DVA

DaVita's stock experienced fluctuations between April and October 2026. It rose from $155.14 in April to a 52-week high of $247.49 in early August. Following Q2 2026 results on August 4, despite beating expectations, the stock dropped from $227.99 to $188.67 due to flat treatment volumes and decreased revenue per treatment. In late August, a new value-based partnership with Humana was announced, leading to a 9.3% surge on September 1, partly due to a $15 million data-breach settlement and the Humana news. Further gains of 1.85% occurred on September 2, linked to strong Q2 earnings and reaffirmed full-year EPS guidance. Profit-taking led to sharp pullbacks on September 17 (down 5.56% to $183.09) and September 24 (down over 4.6% to $174.67). As of October 1, the stock was $176.35, and on October 8, DaVita activated emergency response efforts ahead of Hurricane Isaias, with the stock trading at $179.25 on October 9 and 10, 2026.